These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 24810715)
1. Chemical strategies for development of ATR inhibitors. Llona-Minguez S; Höglund A; Jacques SA; Koolmeister T; Helleday T Expert Rev Mol Med; 2014 May; 16():e10. PubMed ID: 24810715 [TBL] [Abstract][Full Text] [Related]
2. The development of ataxia telangiectasia mutated kinase inhibitors. Andrs M; Korabecny J; Nepovimova E; Jun D; Hodny Z; Moravcova S; Hanzlikova H; Kuca K Mini Rev Med Chem; 2014; 14(10):805-11. PubMed ID: 25138084 [TBL] [Abstract][Full Text] [Related]
3. Molecular Pathways: Targeting ATR in Cancer Therapy. Karnitz LM; Zou L Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996 [TBL] [Abstract][Full Text] [Related]
4. Targeting ATR in DNA damage response and cancer therapeutics. Fokas E; Prevo R; Hammond EM; Brunner TB; McKenna WG; Muschel RJ Cancer Treat Rev; 2014 Feb; 40(1):109-17. PubMed ID: 23583268 [TBL] [Abstract][Full Text] [Related]
5. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment. Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572 [TBL] [Abstract][Full Text] [Related]
6. Targeting the S and G2 checkpoint to treat cancer. Chen T; Stephens PA; Middleton FK; Curtin NJ Drug Discov Today; 2012 Mar; 17(5-6):194-202. PubMed ID: 22192883 [TBL] [Abstract][Full Text] [Related]
7. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. Charrier JD; Durrant SJ; Golec JM; Kay DP; Knegtel RM; MacCormick S; Mortimore M; O'Donnell ME; Pinder JL; Reaper PM; Rutherford AP; Wang PS; Young SC; Pollard JR J Med Chem; 2011 Apr; 54(7):2320-30. PubMed ID: 21413798 [TBL] [Abstract][Full Text] [Related]
8. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. Foote KM; Nissink JWM; McGuire T; Turner P; Guichard S; Yates JWT; Lau A; Blades K; Heathcote D; Odedra R; Wilkinson G; Wilson Z; Wood CM; Jewsbury PJ J Med Chem; 2018 Nov; 61(22):9889-9907. PubMed ID: 30346772 [TBL] [Abstract][Full Text] [Related]
10. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806 [TBL] [Abstract][Full Text] [Related]
12. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. Gorecki L; Andrs M; Rezacova M; Korabecny J Pharmacol Ther; 2020 Jun; 210():107518. PubMed ID: 32109490 [TBL] [Abstract][Full Text] [Related]
13. Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR). Ramachandran SA; Jadhavar PS; Singh MP; Sharma A; Bagle GN; Quinn KP; Wong PY; Protter AA; Rai R; Pham SM; Lindquist JN Bioorg Med Chem Lett; 2017 Feb; 27(4):750-754. PubMed ID: 28131712 [TBL] [Abstract][Full Text] [Related]
14. Sulfoximines as ATR inhibitors: Analogs of VE-821. Hendriks CMM; Hartkamp J; Wiezorek S; Steinkamp AD; Rossetti G; Lüscher B; Bolm C Bioorg Med Chem Lett; 2017 Jun; 27(12):2659-2662. PubMed ID: 28479198 [TBL] [Abstract][Full Text] [Related]
15. Targeted cancer therapies based on the inhibition of DNA strand break repair. O'Connor MJ; Martin NM; Smith GC Oncogene; 2007 Dec; 26(56):7816-24. PubMed ID: 18066095 [TBL] [Abstract][Full Text] [Related]
16. Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity. Patel A; Seraia E; Ebner D; Ryan AJ Int J Cancer; 2020 Sep; 147(5):1474-1484. PubMed ID: 32159854 [TBL] [Abstract][Full Text] [Related]
17. Targeting ATR in patients with cancer. Ngoi NYL; Pilié PG; McGrail DJ; Zimmermann M; Schlacher K; Yap TA Nat Rev Clin Oncol; 2024 Apr; 21(4):278-293. PubMed ID: 38378898 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways. Ito SS; Nakagawa Y; Matsubayashi M; Sakaguchi YM; Kobashigawa S; Matsui TK; Nanaura H; Nakanishi M; Kitayoshi F; Kikuchi S; Kajihara A; Tamaki S; Sugie K; Kashino G; Takahashi A; Hasegawa M; Mori E; Kirita T J Biol Chem; 2020 Sep; 295(37):12946-12961. PubMed ID: 32675286 [TBL] [Abstract][Full Text] [Related]
19. ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Blackford AN; Jackson SP Mol Cell; 2017 Jun; 66(6):801-817. PubMed ID: 28622525 [TBL] [Abstract][Full Text] [Related]
20. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy. Ashwell S; Zabludoff S Clin Cancer Res; 2008 Jul; 14(13):4032-7. PubMed ID: 18593978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]